India emerging as global research hub for diabetes, precision medicine: Dr Jitendra



21/11/2026

BENGALURU, Nov 20: India is emerging as a global research hub in diabetes, genetic disorders and next-generation healthcare solutions, with more than a dozen diabetes-related research projects underway under the Ministry of Science and Technology, Union Minister Dr. Jitendra Singh said on Friday.
Addressing the inaugural session of RSSDI 2026, being held in Bengaluru from November 19 to 22, Singh said research was increasingly focusing on preventing and managing diabetes through molecular and genetic approaches.
He said India's large population and genetic diversity offered a unique opportunity to generate scientific insights and develop healthcare solutions with relevance for both the country and the world. Preventing obesity and diabetes among young people, he added, was a national responsibility requiring collective efforts beyond the medical fraternity.
The minister said India had significantly strengthened its scientific and healthcare capabilities, moving from dependence on external solutions towards developing indigenous vaccines, therapies, antibiotics and advanced medical technologies.
Referring to the country's DNA-based COVID-19 vaccine, biosimilars, genetic therapy research and India Genome Study, he said the expanding research ecosystem was addressing complex health challenges through indigenous innovation. He also highlighted progress in vaccine development for diseases such as HPV, dengue and malaria.
Singh said advances in precision medicine and molecular-level interventions were opening new avenues for understanding Type 2 diabetes and associated metabolic disorders, particularly among younger populations. He called for stronger collaboration among government research institutions, private researchers, clinicians, startups and medical associations to translate scientific discoveries into practical healthcare solutions.
Among the research initiatives highlighted by the minister was an Indo-Danish collaborative study examining changes in gut microbiota among prediabetic and diabetic patients in India.
He also referred to DBT-supported research involving genetically engineered E. coli Nissle 1917 designed to produce GLP-1, exploring the potential of probiotic-based delivery of therapeutic molecules. Research at BRIC-THSTI is also examining the expression of GLP-1 analogues in gut-associated bacteria.
The minister highlighted studies exploring interventions from preconception to early childhood to reduce cardiometabolic risks, including elevated blood glucose, blood pressure and obesity. He also referred to the EINSTEIN study in rural Mysuru and research examining the impact of maternal nutrition during pregnancy on the metabolic health of children.
Other projects include research on biomarkers to predict Type 2 diabetes among women with a history of gestational diabetes, studies examining the relationship between diabetes and metabolic dysfunction-associated fatty liver disease, and investigations into insulin resistance and insulin signalling.
Singh also referred to research exploring macrophage Gi signalling as a potential therapeutic target for obesity and Type 2 diabetes, as well as efforts to develop temperature-resilient insulin to facilitate storage and transportation. Startups are also exploring oral insulin, he said.
Highlighting India's progress in affordable treatment, the minister referred to indigenous biosimilar development, including liraglutide and insulin Lispro, and stressed the importance of institutional support and technological innovation in advancing diabetes care.
The conference brought together diabetologists, clinicians, researchers, academicians and healthcare professionals from India and abroad. Those present included Karnataka Minister for Greater Bengaluru Development and Parliamentary Affairs Krishna Byre Gowda and MP Dr. C. N. Manjunath. The inaugural programme also featured fellowship distribution, recognition of awardees and the release of books and guidelines.
Share This Story |
|
Comment On This Story |
|
|
|
|